PUBLISHER: IMARC | PRODUCT CODE: 1370418
PUBLISHER: IMARC | PRODUCT CODE: 1370418
The global cytokine market size reached US$ 83.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 130.5 Billion by 2028, exhibiting a growth rate (CAGR) of 7.66% during 2023-2028.
A cytokine refers to a group of proteins, peptides, or glycoproteins released by specific cells to control the growth and activity of the immune system and blood cells. It can regulate immunity, inflammation, and hematopoiesis on account of its high-affinity picomolar concentrations. It is usually injected under the skin or into muscles or veins to help prevent or manage chemotherapy side effects and treat cancer. It also boosts anti-cancer activities by sending signals that make abnormal cells die and normal cells live longer. Presently, it is gaining widespread adoption in cell and gene therapy for the expansion and differentiation of various cell types, ex vivo cultures, and other therapeutic approaches.
The coronavirus disease (COVID-19) is transmitted via droplets that can induce the excessive production of proinflammatory cytokines and lead to acute respiratory distress syndrome (ARDS) aggravation and tissue damage. As tissue damage can result in multi-organ failure and death, there is a rise in the demand for solutions that target cytokines to manage patients, improve survival rates, and reduce mortality. Apart from this, the increasing prevalence of cancer, in confluence with the escalating demand for minimally invasive surgeries (MIS) that provide less post-operative pain and complications and faster recovery time, is contributing to the market growth. Moreover, as cytokines act as diagnostic, prognostic, and therapeutic agents and biomarkers for health and diseases, they are gaining traction in diverse functions, including immune cell differentiation, inflammation, angiogenesis, tumorigenesis, neurobiology, and viral pathogenesis. Besides this, the rising cases of atopic dermatitis (AD), a recurrent, chronic, and inflammatory skin disease that processes with severe itchiness, is driving the demand for new cytokines in the pathogenesis of AD and developing improved therapeutic targets.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cytokine market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on cytokine type, therapeutic application and end user.
Tumor Necrosis Factor-TNF
Interleukins-Il
Interferons-IFN
Epidermal Growth Factor-EGF
Others
Cancer
Asthma and Airway Inflammation
Arthritis
Others
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
How has the global cytokine market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cytokine market?
What are the key regional markets?
What is the breakup of the market based on the cytokine type?
What is the breakup of the market based on the therapeutic application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cytokine market and who are the key players?
What is the degree of competition in the industry?